Nedd4 activators represent a diverse chemical class that exert their primary biological effect by modulating the activity of the E3 ubiquitin-protein ligase known as Neural precursor cell expressed, developmentally down-regulated 4, or Nedd4. This particular ligase is a crucial component in the ubiquitin-proteasome system, which is responsible for tagging specific proteins for degradation and thus maintaining cellular protein homeostasis. The chemical agents within the Nedd4 activator class are characterized by their ability to enhance the enzymatic function of Nedd4, often by inducing its phosphorylation state. This phosphorylation can lead to an increase in the ligase's substrate recognition and ubiquitination activity. The spectrum of Nedd4 activators includes various biomolecules, such as growth factors, hormones, and small-molecule inhibitors, each interacting with unique cellular pathways but converging on the modulation of Nedd4.
The biochemical pathways engaged by these activators are complex and varied, with some acting directly on the Nedd4 protein and others exerting their effects indirectly through upstream signaling cascades. For instance, activators like EGF, insulin, and IGF-1 function through the activation of receptor tyrosine kinases, which in turn initiate the PI3K/AKT signaling pathway-a pathway that is well-established in its role in phosphorylating and activating various downstream targets, including Nedd4. Once activated, Nedd4 can attach ubiquitin to specific lysine residues on substrate proteins, marking them for degradation. On the other hand, certain small-molecule inhibitors, which ostensibly serve to impede enzymatic pathways, can paradoxically result in the upregulation of compensatory mechanisms within the cell that lead to the activation of Nedd4. These include inhibitors of MEK (such as PD98059 and U0126), PI3K (like LY294002 and Wortmannin), and mTOR (like Rapamycin), which, through complex feedback and regulatory loops within the cell's signaling networks, may inadvertently enhance the activity of the PI3K/AKT pathway and, consequently, Nedd4 activation.
関連項目
产品名称 | CAS # | 产品编号 | 数量 | 价格 | 应用 | 排名 |
---|---|---|---|---|---|---|
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $153.00 $1224.00 $12239.00 | 82 | |
胰岛素受体激活会刺激 PI3K/AKT 信号通路。AKT 可使 Nedd4 磷酸化,从而增加其泛素连接酶活性,促进靶蛋白的泛素化。 | ||||||
Bradykinin (1-3) | 23815-91-0 | sc-391193 sc-391193A sc-391193B | 5 mg 25 mg 100 mg | $151.00 $444.00 $1366.00 | ||
Bradykinin与其B2受体结合,可激活PLC,进而刺激PKC。PKC已被证明可磷酸化泛素-蛋白酶体系统的成分,从而间接增强Nedd4的活性。 | ||||||
Ob (hBA-147) | sc-4912 | 1000 µg | $253.00 | 1 | ||
瘦素受体信号激活JAK2,继而激活STAT3,后者可与Nedd4相互作用。这种相互作用可促进Nedd4的E3连接酶活性,从而增加其底物的泛素化。 | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 可抑制 MEK,从而通过减少负反馈回路间接上调 PI3K/AKT 信号。AKT 活性的增强会导致 Nedd4 的磷酸化和激活。 | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002是一种PI3K抑制剂,可以调节PI3K/AKT通路的活性。在PI3K抑制后,AKT信号的矛盾上调已被注意到,这可能会间接增强Nedd4的活性。 | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 可抑制 MEK1/2,从而导致其他通路(包括 PI3K/AKT 通路)的潜在补偿性上调。这种上调可能会增强 Nedd4 的磷酸化和活性。 | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin 可抑制 PI3K,导致复杂的反馈回路,从而激活补偿机制,有可能增加 PI3K/AKT 信号传导并增强 Nedd4 的活性。 | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
雷帕霉素抑制mTOR,从而减少PI3K/AKT通路的负反馈。因此,AKT可以上调,从而可能通过磷酸化增强Nedd4的活性。 |